(News Bulletin 247) – TheraVet, a specialist in the treatment of osteoarticular diseases in companion animals, took off on the stock market on Tuesday following the signing of a distribution agreement covering 24 countries internationally.
Under the terms of the agreement, concluded with the French Vetpharma, its Biocera-Vet product range, a line of organic and calcium phosphate-based bone substitutes, will now be available on all continents.
The biotechnology company, based in Wallonia, stresses that the agreement will notably open the doors to high-potential territories, such as the Scandinavian countries, Brazil, South Africa, Australia and Japan.
In detail, the agreement concerns Norway, Sweden, Denmark and Finland, Eastern Europe (Poland, Bulgaria, Romania, Czech Republic, Croatia and Hungary), Latin America (Brazil, Mexico, Colombia, Argentina, Chile and Peru), South Africa, Australia and some Asian countries (Japan, Indonesia, Philippines, Vietnam, Thailand and South Korea).
The news led to a surge in the company’s share price, which soared by more than 85% at the time of its last available quotation, shortly before 12:30 p.m., in volumes nearly 40 times higher than those of the last sessions.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
